Page last updated: 2024-11-13

ly2886721

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID49837968
CHEMBL ID2396989
SCHEMBL ID966802
MeSH IDM000603700

Synonyms (37)

Synonym
HY-13240
chembl2396989 ,
bdbm50012647
ly 2886721
LY2886721 ,
ly-2886721
1262036-50-9
BCP9000879
2cq62iwb67 ,
unii-2cq62iwb67
CS-0458
S2156
n-(3-((4as,7as)-2-amino-4a,5,7,7a-tetrahydro-4h-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide
n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide
n-{3-[(4as,7as)-2-amino-4h,4ah,5h,7h,7ah-furo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide
gtpl6475
MLS006011070
smr004702860
NIDRNVHMMDAAIK-YPMLDQLKSA-N ,
2-pyridinecarboxamide, n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-
SCHEMBL966802
AC-33097
n-{3-[(4as,7as)-2-amino-4a,5-dihydro-4h-furo[3,4-d][1,3]thiazin-7a(7h)-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide
3ys ,
n-[3-[(4as,7as)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide
DTXSID70155117
J-522974
EX-A029
AKOS027422646
mfcd22124078
DB12547
Q27082776
BCP02507
HMS3884J09
CCG-268530
AS-56127
A889495
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cathepsin DHomo sapiens (human)IC50 (µMol)300.00000.00000.931610.0000AID1653764; AID1811772
Beta-secretase 1Homo sapiens (human)IC50 (µMol)0.01500.00061.619410.0000AID1139860; AID1328685; AID1328686; AID1653762; AID1811771
Beta-secretase 1Mus musculus (house mouse)IC50 (µMol)0.01070.01070.06260.1260AID1811780
Beta-secretase 2Homo sapiens (human)IC50 (µMol)0.01020.00090.64922.8800AID1653763
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (28)

Processvia Protein(s)Taxonomy
autophagosome assemblyCathepsin DHomo sapiens (human)
proteolysisCathepsin DHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IICathepsin DHomo sapiens (human)
insulin receptor recyclingCathepsin DHomo sapiens (human)
lipoprotein catabolic processCathepsin DHomo sapiens (human)
positive regulation of apoptotic processCathepsin DHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCathepsin DHomo sapiens (human)
regulation of establishment of protein localizationCathepsin DHomo sapiens (human)
insulin catabolic processCathepsin DHomo sapiens (human)
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
proteolysisBeta-secretase 2Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 2Homo sapiens (human)
protein processingBeta-secretase 2Homo sapiens (human)
peptide hormone processingBeta-secretase 2Homo sapiens (human)
melanosome organizationBeta-secretase 2Homo sapiens (human)
glucose homeostasisBeta-secretase 2Homo sapiens (human)
negative regulation of amyloid precursor protein biosynthetic processBeta-secretase 2Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
cysteine-type endopeptidase activityCathepsin DHomo sapiens (human)
protein bindingCathepsin DHomo sapiens (human)
peptidase activityCathepsin DHomo sapiens (human)
aspartic-type peptidase activityCathepsin DHomo sapiens (human)
aspartic-type endopeptidase activityCathepsin DHomo sapiens (human)
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 2Homo sapiens (human)
protein bindingBeta-secretase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
collagen-containing extracellular matrixCathepsin DHomo sapiens (human)
extracellular regionCathepsin DHomo sapiens (human)
extracellular spaceCathepsin DHomo sapiens (human)
lysosomeCathepsin DHomo sapiens (human)
lysosomal membraneCathepsin DHomo sapiens (human)
endosome membraneCathepsin DHomo sapiens (human)
endosome lumenCathepsin DHomo sapiens (human)
specific granule lumenCathepsin DHomo sapiens (human)
melanosomeCathepsin DHomo sapiens (human)
lysosomal lumenCathepsin DHomo sapiens (human)
membrane raftCathepsin DHomo sapiens (human)
collagen-containing extracellular matrixCathepsin DHomo sapiens (human)
extracellular exosomeCathepsin DHomo sapiens (human)
tertiary granule lumenCathepsin DHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin DHomo sapiens (human)
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
endoplasmic reticulumBeta-secretase 2Homo sapiens (human)
Golgi apparatusBeta-secretase 2Homo sapiens (human)
plasma membraneBeta-secretase 2Homo sapiens (human)
membraneBeta-secretase 2Homo sapiens (human)
melanosome membraneBeta-secretase 2Homo sapiens (human)
plasma membraneBeta-secretase 2Homo sapiens (human)
trans-Golgi networkBeta-secretase 2Homo sapiens (human)
endosomeBeta-secretase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID1811777Stability in dog liver microsomes at 2 uM measured upto 30 mins in presence of NADPH by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811780Inhibition of BACE1 in mouse primary cortical neuron assessed as reduction in Amyloid-beta level incubated for 24 hrs by sandwich ELISA assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811778Stability in human liver microsomes at 2 uM measured upto 30 mins in presence of NADPH by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811771Inhibition of recombinant human BACE1 using (MCA)-S-E-V-N-L-D-A-E-F-R-K(dinitrophenol)-R-R-R-R-NH2 as substrate incubated for 8 hrs by FRET assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1653763Inhibition of human BACE22020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
AID1811783Volume of distribution at steady state in rat at 2 mg/kg, iv by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811769Lipophilicity, log P of the compound2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811807Ratio of free drug concentration in CSF to plasma of dog2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1653762Inhibition of human BACE1 (1 to 460 residues) expressed in HEK293 cells using mcaFRET peptide as substrate after 20 hrs by FRET assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
AID1328686Inhibition of BACE1 (unknown origin)2016Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23
Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors.
AID1811774Permeability in MDCK cells2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811784Clearance in dog at 1 mg/kg, iv by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID754447Inhibition of BACE1 in alzheimer's disease patient assessed as reduction of CSF Abeta level at 15 mg/kg2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease.
AID1811792Bioavailability in rat2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811779Selectivity ratio of IC50 for human CathepsinD to IC50 for human BACE12021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1653764Inhibition of human cathepsin D2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
AID1811790Inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated for 10 mins followed by substrate and NADPH addition measured after 3 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811785Volume of distribution at steady state in dog at 1 mg/kg, iv by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811793Unbound fraction in rat plasma2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811781Drug accumulation in human HepG2 cells lysosomes assessed as maximum fluorescence response after 24 hrs by Lysotracker Green DND-26 dye based assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811791Unbound fraction in human plasma2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1139860Inhibition of Fc domain of IgG1-fused human BACE1 (1 to 460) expressed in HEK293 cells preincubated for 10 mins followed by enzyme addition measured after 16 to 24 hrs by FRET assay2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
The evolution of amidine-based brain penetrant BACE1 inhibitors.
AID1811776Stability in rat liver microsomes at 2 uM measured upto 30 mins in presence of NADPH by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811795Unbound fraction in mouse brain2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811772Inhibition of human Cathepsin D by FRET assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811806Unbound fraction in dog plasma2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811775Stability in mouse liver microsomes at 2 uM measured upto 30 mins in presence of NADPH by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811788Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 10 mins followed by substrate and NADPH addition measured after 3 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811770Dissociation constant, pKa of compound2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID754446Inhibition of BACE1 in alzheimer's disease patient assessed as reduction of CSF Abeta level at 35 mg/kg2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease.
AID1328685Inhibition of human recombinant BACE1 by FRET assay2016Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23
Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors.
AID1811794Unbound fraction in mouse plasma2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811789Inhibition of CYP2D6 in human liver microsomes at 10 uM using bufuralol as substrate preincubated for 10 mins followed by substrate and NADPH addition measured after 3 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811782Clearance in rat at 2 mg/kg, iv by LC-MS/MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811773Substrate activity at human P-gp expressed in MDCK cells assessed as efflux ratio of apparent permeability across apical to basolateral over basolateral to apical membrane2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1811786Invivo inhibition of BACE1 in dog assessed as reduction in amyloid-beta level at 3 mg/kg, po measured upto 48 hrs by sandwich ELISA assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (42.86)24.3611
2020's4 (57.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.14 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]